Guanfacine extended release for the reduction of aggression, attention-deficit/hyperactivity disorder symptoms, and self-injurious behavior in Prader-Willi syndrome-a retrospective cohort study - Singh D, Wakimoto Y, Filangieri C, Pinkhasov A, Angulo M.

OBJECTIVE: To examine the role of Guanfacine Extended Release (GXR) in the management of behavioral disturbances in patients with Prader-Willi Syndrome (PWS). METHODS: Twenty from a total of 27 individuals with genetically confirmed PWS, 6-26 years...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news